• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SLC22A1 Gene Record

  • Summary
  • Interactions
  • Claims
  • SLC22A1 6580 Druggable Genome

    Alternate Names:

    6580
    SOLUTE CARRIER FAMILY 22 MEMBER 1
    SLC22A1
    HOCT1
    OCT1
    oct1_cds
    602607
    10963
    ENSG00000175003
    OTTHUMG00000015947
    PA329
    1019
    O15245
    Organic cation transporter 1
    SOLUTE CARRIER FAMILY 22 MEMBER 1 ISOFORM A [SOURCE:REFSEQ_PEPTIDE;ACC:NP_003048]

    Gene Info:

    GuideToPharmacology Gene Category Name Organic cation transporters (OCT)
    GuideToPharmacology Gene Category ID 196
    Human Readable Name DRUGGABLE GENOME
    Gene Biotype PROTEIN_CODING
    (4 More Sources)

    Gene Categories: Category Details

    TRANSPORTER
    KINASE
    EXTERNAL SIDE OF PLASMA MEMBRANE
    DRUGGABLE GENOME

    Publications:

    Takeuchi K et al., 2011, Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent., Drug Metab Dispos
    Shu Y et al., 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics., Clin Pharmacol Ther
    Sundelin E et al., 2017, Genetic Polymorphisms in Organic Cation Transporter 1 Attenuates Hepatic Metformin Exposure in Humans., Clin Pharmacol Ther
    Becker ML et al., 2010, Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response., Pharmacogenet Genomics
    Pedersen AJT et al., 2018, The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial., Basic Clin Pharmacol Toxicol
    Chien HC et al., 2016, Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells., Drug Metab Dispos
    Tarasova L et al., 2012, Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients., Pharmacogenet Genomics
    Tzvetkov MV et al., 2009, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin., Clin Pharmacol Ther
    Todd JN et al., 2014, An update on the pharmacogenomics of metformin: progress, problems and potential., Pharmacogenomics
    Shikata E et al., 2007, Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin., J Hum Genet
    Christensen MM et al., 2011, The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c., Pharmacogenet Genomics
    Dorosz J et al., 2010, Membrane interactions of novicidin, a novel antimicrobial peptide: phosphatidylglycerol promotes bilayer insertion., J Phys Chem B
    Santoro AB et al., 2018, Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort., Br J Clin Pharmacol
    Gong L et al., 2012, Metformin pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
    Becker ML et al., 2009, Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus., Pharmacogenomics J
    Dujic T et al., 2017, Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis., Clin Pharmacol Ther
    Clark RE et al., 2008, Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia., Leuk Lymphoma
    Ravegnini G et al., 2019, An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor., Pharmacogenomics J
    Cargnin S et al., 2018, Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis., Pharmacol Res
    Verboom MC et al., 2019, Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors., Pharmacogenomics J
    Qiu HB et al., 2018, Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1., Pharmacogenomics J
    Giannoudis A et al., 2013, The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia., Blood
    Di Paolo A et al., 2014, The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia., Pharmacogenomics J
    Kim DH et al., 2009, Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia., Clin Cancer Res
    Matthaei J et al., 2019, OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil., Clin Pharmacol Ther
    Tzvetkov MV et al., 2011, Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol., Clin Pharmacol Ther
    Shen CH et al., 2016, Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy., Epilepsy Res
    Tzvetkov MV et al., 2012, Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron., Pharmacogenomics J
    Herraez E et al., 2013, Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib., Hepatology
    Tzvetkov MV et al., 2013, Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration., Biochem Pharmacol
  • TETRYLAMMONIUM   SLC22A1

    Interaction Score: 2.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21422191


    Sources:
    DTC

  • CHLOROGUANIDE   SLC22A1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29882324


    Sources:
    PharmGKB

  • METFORMIN   SLC22A1

    Interaction Score: 1.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17609683 28380657 19898263 28834135 26700958 22735389 19536068 24624919 17111267 21989078 20690652 29352482 22722338 19381165 27859023


    Sources:
    PharmGKB

  • ELTROMBOPAG   SLC22A1

    Interaction Score: 1.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21422191


    Sources:
    DTC

  • TROPISETRON   SLC22A1

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20921968


    Sources:
    PharmGKB

  • IMATINIB   SLC22A1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18398725 30237583 29427770 30713339 28762371 23223357 24589908 19584153


    Sources:
    PharmGKB

  • SELEGILINE   SLC22A1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • AMANTADINE   SLC22A1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CLONIDINE   SLC22A1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • TRAMADOL   SLC22A1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21562485


    Sources:
    PharmGKB

  • MORPHINE   SLC22A1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23835420


    Sources:
    PharmGKB

  • LAMOTRIGINE   SLC22A1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27610747


    Sources:
    PharmGKB

  • LAMIVUDINE   SLC22A1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LEVODOPA   SLC22A1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • SORAFENIB   SLC22A1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23532667


    Sources:
    PharmGKB

  • Ensembl: ENSG00000175003

    • Version: 101_38

    Alternate Names:
    SLC22A1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000175003

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000175003 Ensembl Gene Id
    SOLUTE CARRIER FAMILY 22 MEMBER 1 ISOFORM A [SOURCE:REFSEQ_PEPTIDE;ACC:NP_003048] Description
    SLC22A1 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GuideToPharmacology: 6580

    • Version: 29-September-2020

    Alternate Names:
    10963 HUGO Gene ID
    10963 HUGO Gene Symbol
    solute carrier family 22 member 1 HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name Organic cation transporters (OCT)
    GuideToPharmacology Gene Category ID 196

    Gene Categories:
    TRANSPORTER

    Publications:

  • PharmGKB: SLC22A1

    • Version: 18-August-2020

    Alternate Names:
    PA329 PharmGKB ID

    Gene Info:

    Publications:
    Matthaei J et al., 2019, OCT1 Deficiency Affects Hepatocellular Concentrations and Pharmacokinetics of Cycloguanil, the Active Metabolite of the Antimalarial Drug Proguanil., Clin Pharmacol Ther
    Shen CH et al., 2016, Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy., Epilepsy Res
    Herraez E et al., 2013, Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib., Hepatology

  • DTC: SLC22A1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Takeuchi K et al., 2011, Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent., Drug Metab Dispos

  • HingoraniCasas: ENSG00000175003

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000175003 Gene Symbol
    SLC22A1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Pharos: SLC22A1

    • Version: 03-September-2020

    Alternate Names:
    Solute carrier family 22 member 1 Gene Name
    O15245 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSPORTER, KINASE

    Publications:

  • GO: SLC22A1

    • Version: 05-September-2020

    Alternate Names:
    OCT1 GO Gene Synonym

    Gene Info:

    Gene Categories:
    EXTERNAL SIDE OF PLASMA MEMBRANE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21